Breaking News Instant updates and real-time market news.

AUTL

Autolus Therapeutics

$12.52

-0.38 (-2.95%)

07:44
01/13/20
01/13
07:44
01/13/20
07:44

Autolus Therapeutics expects to start Phas 1 trial of AUTO1NG in 1H20

Autolus Therapeutics is presenting at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2020 at 5:00 pm Pacific Time where Christian Itin, the chairman and chief executive officer of Autolus, will provide an outlook for 2020. Autolus is advancing its lead program, AUTO1 in relapsed/refractory adult acute lymphoblastic leukemia patients, into a potential pivotal trial in the United Kingdom and the United States. During the year, the company also expects to report further clinical data across several programs at key medical conferences, including AUTO1 in adult ALL, AUTO1 in pediatric ALL, AUTO3 in diffuse large B cell lymphoma and AUTO4 in Peripheral T cell lymphoma. Additionally, Autolus expects to commence a Phase 1 clinical trial of AUTO1NG in pediatric ALL in the first half of 2020, plans for a go/no-go decision on Phase 2 initiation of AUTO3 in DLBCL in the middle of 2020, and expects to initiate two new Phase 1 clinical trials with next generation programs, AUTO6NG across certain solid tumor settings and AUTO8 in multiple myeloma, both in the second half of 2020. Autolus will continue in 2020 to progress additional next generation programs through pre-clinical development and expand its suite of cell programming technologies to include programming modules designed for allogeneic applications. A first novel allogeneic application is expected to enter the clinic in the fourth quarter of 2020.

  • 13

    Jan

AUTL Autolus Therapeutics
$12.52

-0.38 (-2.95%)

09/12/19
HCWC
09/12/19
NO CHANGE
Target $24
HCWC
Buy
Autolus' Woodford overhang in the rearview, says H.C. Wainwright
A filing on September 9 places the Woodford Patient Capital Trust Plc ownership of Autolus Therapeutics at 4.7%, down from about 24%, which should put a near-term floor on the stock, H.C. Wainwright analyst Debjit Chattopadhyay tells investors in a research note. The suspension of redemption from Woodford's flagship equity fund had been a principal contributor to the drawdown in Autolus shares during Q2, says the analyst. However, with the overhang now in the review, investors can revisit the company's pipeline, contends Chattopadhyay. The analyst has a Buy rating on the shares with a $24 price target.
09/23/19
NEED
09/23/19
INITIATION
NEED
Buy
Autolus Therapeutics initiated with a Buy at Needham
09/23/19
NEED
09/23/19
INITIATION
Target $26
NEED
Buy
Autolus Therapeutics initiated with a Buy at Needham
Needham analyst Chad Messer initiated Autolus Therapeutics with a Buy rating and a price target of $26, saying the stock may prove to be one of the "most valuable pure play CAR-T investments" available. The analyst cites the company's efforts in developing solutions for CAR-T challenges, which include reducing toxicity, improving T-cell persistence, overcoming resistance, finding new tumor antigen targets, and achieving efficacy in solid tumors. Messer expects Autolus' upcoming data updates - starting with December at ASH - to provide upside for the stock.

TODAY'S FREE FLY STORIES

TRIP

TripAdvisor

$30.53

-0.38 (-1.23%)

11:35
01/21/20
01/21
11:35
01/21/20
11:35
Options
TripAdvisor put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Feb

11:34
01/21/20
01/21
11:34
01/21/20
11:34
Conference/Events
Stephens life science analyst to hold a group luncheon »

Life Science Tools &…

YARIY

Yara

$0.00

(0.00%)

11:33
01/21/20
01/21
11:33
01/21/20
11:33
Hot Stocks
Yara announces investigation by Spanish competition regulator »

Yara announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VALE

Vale

$13.37

-0.275 (-2.02%)

11:29
01/21/20
01/21
11:29
01/21/20
11:29
Periodicals
Charges filed against Vale, TUV SUD for deadly dam collapse, WSJ reports »

Individuals at Vale and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBER

Uber

$36.94

1.82 (5.18%)

11:28
01/21/20
01/21
11:28
01/21/20
11:28
Recommendations
Uber analyst commentary  »

Uber financial discipline…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

LVS

Las Vegas Sands

$70.95

-3.12 (-4.21%)

11:25
01/21/20
01/21
11:25
01/21/20
11:25
Options
Las Vegas Sands call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRRA

Sierra Oncology

$0.39

-0.0109 (-2.73%)

11:25
01/21/20
01/21
11:25
01/21/20
11:25
Conference/Events
Sierra Oncology to host virtual special shareholder meeting »

Virtual Special…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

11:25
01/21/20
01/21
11:25
01/21/20
11:25
Conference/Events
The National Economists Club to hold a luncheon meeting »

Gregory Daco, Chief U.S.…

11:25
01/21/20
01/21
11:25
01/21/20
11:25
Conference/Events
CFA Society of Columbus to hold luncheon meeting on 2020 fixed income »

Thomas Tzitzouris,…

INTC

Intel

$60.68

1.1 (1.85%)

, LB

L Brands

$20.40

0.24 (1.19%)

11:18
01/21/20
01/21
11:18
01/21/20
11:18
On The Fly
Intel, L Brands, Costco upgrades among today's top analyst calls »

Check out today's top…

INTC

Intel

$60.68

1.1 (1.85%)

LB

L Brands

$20.40

0.24 (1.19%)

COST

Costco

$311.46

6.78 (2.23%)

DG

Dollar General

$157.97

(0.00%)

LL

Lumber Liquidators

$8.46

-0.89 (-9.52%)

MS

Morgan Stanley

$55.51

-2 (-3.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 23

    Jan

  • 12

    Feb

  • 27

    Feb

  • 05

    Mar

LRCX

Lam Research

$311.12

3.14 (1.02%)

11:17
01/21/20
01/21
11:17
01/21/20
11:17
Recommendations
Lam Research analyst commentary  »

Lam Research price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
01/21/20
01/21
11:17
01/21/20
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

11:16
01/21/20
01/21
11:16
01/21/20
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COLM

Columbia Sportswear

$97.10

1.51 (1.58%)

, VFC

VF Corp.

$94.20

-0.05 (-0.05%)

11:15
01/21/20
01/21
11:15
01/21/20
11:15
Hot Stocks
Columbia Sportswear rises as VF Corp. review leads to speculation »

Shares of Columbia…

COLM

Columbia Sportswear

$97.10

1.51 (1.58%)

VFC

VF Corp.

$94.20

-0.05 (-0.05%)

KTB

Kontoor Brands

$42.31

0.595 (1.43%)

YETI

Yeti

$36.33

2.1 (6.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 06

    Feb

RCL

Royal Caribbean

$129.08

-5.96 (-4.41%)

11:15
01/21/20
01/21
11:15
01/21/20
11:15
Options
Royal Caribbean put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

11:15
01/21/20
01/21
11:15
01/21/20
11:15
General news
Treasury announced $80 B in 4- and 8-week bills for Thursday's auctions »

Treasury announced $80 B…

11:15
01/21/20
01/21
11:15
01/21/20
11:15
General news
U.S. equities opened with losses »

U.S. equities opened with…

11:15
01/21/20
01/21
11:15
01/21/20
11:15
General news
Breaking General news story  »

6-Month Bill Auction to…

11:15
01/21/20
01/21
11:15
01/21/20
11:15
General news
Breaking General news story  »

3-Month Bill Auction to…

11:15
01/21/20
01/21
11:15
01/21/20
11:15
General news
Breaking General news story  »

3-Month Bill Auction to…

11:15
01/21/20
01/21
11:15
01/21/20
11:15
General news
Breaking General news story  »

6-Month Bill Auction to…

DISCB

Discovery Inc.

$37.80

(0.00%)

11:14
01/21/20
01/21
11:14
01/21/20
11:14
Hot Stocks
Breaking Hot Stocks news story on Discovery Inc. »

Discovery Communications…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

COST

Costco

$311.47

6.79 (2.23%)

, DG

Dollar General

$158.20

0.23 (0.15%)

11:13
01/21/20
01/21
11:13
01/21/20
11:13
Upgrade
Costco, Dollar General rating change  »

Costco upgraded to…

COST

Costco

$311.47

6.79 (2.23%)

DG

Dollar General

$158.20

0.23 (0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 05

    Mar

DCPH

Deciphera

$68.42

-0.97 (-1.40%)

11:12
01/21/20
01/21
11:12
01/21/20
11:12
Recommendations
Deciphera analyst commentary  »

Deciphera price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DISCB

Discovery Inc.

$37.80

(0.00%)

11:04
01/21/20
01/21
11:04
01/21/20
11:04
Hot Stocks
Breaking Hot Stocks news story on Discovery Inc. »

Discovery Communications…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.